Home News Industry News Recently Spun Out Axikin Obtains $3M Series A Financing

Recently Spun Out Axikin Obtains $3M Series A Financing

January 22, 2009

The team used cryogenic electron microscopy, a method to look at the structure of biological molecules in high-resolution, to analyze AsCas12f and engineer their new version. The DMS “heatmap” illustrates how all single mutations affected genome-editing activity. Blue squares indicate an undesirable mutation, while red ones represent desirable changes. The darker the color, the greater the effect. [Hino et al. 2023]

Company was formed with Actimis’ preclinical pipeline.

Axikin Pharmaceuticals will receive $3 million through a series A private placement of its stock. The company was formed as a spinout from Actimis Pharmaceuticals following the acquisition of Actimis’ lead program by Boehringer Ingelheim in a structured buyout in June 2008.

Axikin’s pipeline includes an advanced preclinical program with multiple small molecule lead candidates and two additional novel target research programs. These programs are expected to have broad applications across respiratory and allergic diseases including asthma, allergic rhinitis, and COPD.

The financing was led by Sanderling Ventures, and additional investors included Mitsui & Co. Venture Partners.

—